Relationship between serum arginase I and l-arginine or exhaled nitric oxide in asthma

Abstract

The relationship between serum arginase I and serum l-arginine or fractional exhaled nitric oxide (FENO) was evaluated cross-sectionally in asthmatic patients. No sex difference was observed in the serum mean levels of arginase I and l-arginine or FENO. Arginase I and FENO were higher in patients 60 or younger years than in those over 60 years. Asthmatic patients were divided into three groups: no steroid therapy, inhalation steroid therapy, and oral steroid therapy. Arginase I, FENO and high-sensitivity-C-reactive protein (hs-CRP) were significantly lower in the inhalation steroid therapy group than in the no steroid therapy group. Correlations were observed between arginase I and FENO, l-arginine, hs-CRP, WBC, and age, and also between FENO and IgE, WBC, and age. A logistic regression analysis revealed the positive association of arginase I with FENO, and the negative association of l-arginine. FENO was positively associated with arginase I and IgE. These results indicated that serum arginase I might influence serum levels of l-arginine and FENO, and that IgE might influence FENO in asthmatic patients.

Phenotypic characteristics of asthma and morbidity are associated with distinct longitudinal changes in L-arginine metabolism

“…For instance, men have been found to have higher FeNO than women in studies of healthy13 and asthma participants 14. Advanced age has been associated with higher ADMA levels in studies of individuals with15 and without asthma 16 17. Studies of L-arginine metabolism and race have revealed conflicting results in populations without asthma with respect to ADMA 18–20.…”

Risk of Malignancy in Patients with Asthma-COPD Overlap Compared to Patients with COPD without Asthma

“…Taken together, neither ICS use, nor specifically the dose used, was associated with any clinically meaningful risk changes for cancer, although some risk estimates had low p -values. Lowering chronic inflammation may decrease the risk of cancer [ 11 , 13 , 14 , 15 , 16 , 17 , 18 ], and thus the more frequent use of oral and inhaled corticosteroids in patients with asthma-COPD overlap may have decreased their risk of cancer events by lowering chronic inflammation. Since our results were neutral, taken together, this could be caused, at least in part, by “neutralization” of a possible increased risk of cancer events in the asthma-COPD overlap patients on one side, and a protective effect of oral corticosteroids and ICS in the same groups of patients on the other side.…”

“…The sub-study was based on the CANTOS randomized controlled trial, which examined 10,061 patients with previous myocardial infarction and an elevated level of hsCRP, to see if inhibition of Interleukin-1-beta driven inflammation could reduce the risk of cardiovascular events [ 12 ]. Similarly, cohort studies have pointed towards a cancer-protective effect of ICS, which has also been shown to lower hsCRP in patients with asthma [ 13 , 14 , 15 , 16 , 17 , 18 ].…”